PSMA-CART cell therapy (Shanghai Bioray Laboratory)

N/A

Report date: 2024/01/31 15:08:20

Base Information

Drug NamePSMA-CART cell therapy (Shanghai Bioray Laboratory)
Drug Alias Name前列腺特异性膜抗原-嵌合抗原受体T细胞疗法-上海生物实验室有限公司Autologous PSMA-specific chimeric antigen cellsPSMA-specific CAR modified autologous T cell therapyPSMA-specific CAR modified autologous T cellsAutologous PSMA-specific chimeric antigen cell therapy +[9] 
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBRL Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesBRL Medicine IncZhejiang University
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A